TIGIT

Sep 07, 2018

Compugen Announces First Patient Dosed with COM701, a First-in-Class Cancer Immunotherapy Antibody, in Phase 1 Clinical Trial

Jul 02, 2018

Compugen Announces FDA Clearance of IND Application for COM701, a First-in-class Immuno-Oncology Therapeutic Antibody

Jan 18, 2018

Compugen Presents New Preclinical Data Demonstrating the Distinctive Features of the PVRIG Pathway in Immuno-Oncology and the Potential of COM701 for Treating Multiple Solid Tumors

Jan 02, 2018

Compugen Announces Presentations at Three Upcoming Cancer Immunotherapy Conferences

Oct 26, 2017

Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month